Search Results

Ampio Pharmaceuticals, Inc. announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”) today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio’s only product development opportunity.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company) today announced that it has selected Ascendia Pharmaceuticals, Inc. (“Ascendia”) to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.

Ampio Pharmaceuticals, Inc. announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended.

Ampio Pharmaceuticals, Inc. announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company’s common stock.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, October 5, 2023 at 3:25 pm ET.

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).